On-Site Drug Testing Olney, MT
Time is money, we can come to you. Accredited Drug Testing provides on-site drug testing services in Olney, MT and throughout the local area for employers who need drug or alcohol testing at their place of business or other location. On-site drug testing methods include urine drug testing, hair drug testing, oral saliva drug testing and breath alcohol testing. Both instant drug test results and laboratory analyzed testing is available. Testing purposes can include pre-employment, random, reasonable suspicion and post-accident.
734 9TH ST W STE 12 21.6 miles
COLUMBIA FALLS, MT 59912
2316 US HIGHWAY 93 N 24.5 miles
KALISPELL, MT 59901
Drug Test Screening Panels Available In Olney, MT
We offer a 5-panel drug test, which screens for the following:
- Amphetamines
- Cocaine
- Marijuana
- Opiates
- PCP
We offer a 10-panel drug test which screens for the following:
- Amphetamines
- Barbituates
- Benzodiazepines
- cocaine
- Marijuana
- MDA
- Methadone
- Methaqualone
- Opiates
- PCP
- Propoxyphene
We offer a 12-panel drug test which screens for the following:
- Amphetamines
- Barbiturates
- Benzodiazepines
- cocaine
- Marijuana
- MDA
- Methadone
- Methaqualone
- Opiates
- PCP
- Propoxyphene
- Meperidine
- Tramadol
** Customized drug testing panels such as bath salts, synthetic marijuana, steroids and other drugs are also available.
Urine or Hair On-site Drug Testing In Olney, MT - You Choose!
Our on-site drug testing services in Olney, MT include urine drug testing, which has a detection period of 1-5 days and hair drug testing which has a detection period of up to 90 days. Negative test results are generally available in 24-48 hours, when analyzed by our SAMHSA Certified Laboratories. Negative instant test results are available immediately, non-negative test results require laboratory confirmation.
Why Use On-Site Drug Testing in Olney, MT?
Time is money and when sending an employee to one of our many drug testing centers in Olney, MT would cause disruption to your business operations or affect your employees work productivity, conducting on-site drug testing will eliminate these issues.
Who Uses On-Site Drug Testing?
- Construction Sites
- Manufacturing Plants
- Power Plants
- Motor Pool Facilities
- Car Dealerships
- Trucking/Transportation Companies
- Schools
- Sports Venues
- Hospitals
- Oil & Gas Drillings Sites
Are you a DOT Regulated Company?
Accredited Drug Testing has trained and qualified collectors who also specialize in providing on-site drug testing services for all DOT modes to include:
- Trucking Industry-FMCSA
- Maritime Industry-USCG
- Aviation Industry-FAA
- Public Transportation-FTA
- Railroad Industry-FRA
- Pipeline Industry-PHMSA
Additional DOT Services:
- DOT Consortium Enrollment
- DOT Physicals
- Supervisor Training
- DOT Drug Policy Development
- MVR Reports
- Employee Training
- Background Checks
- FMCSA Clearinghouse Verification/Search
How To Schedule On-Site Drug Testing In Olney, MT?
Step 1 - Call our on-site coordinator at (800)221-4291
Step 2 - Have at least 10 employees needing to be tested (recommended)
Step 3 - Provide the date, location and time of the requested on-site drug testing services
In addition to on-site drug testing in Olney, MT, we also have drug testing centers available at the following locations.
Were you looking, instead, for:
Local Area Info: Olney's lesions
Olney's lesions, also known as NMDA receptor antagonist neurotoxicity (NAN), are a potential form of brain damage due to drugs that have been studied experimentally and have produced neuronal damage, yet are administered by doctors to humans in the settings of pharmacotherapy and of anesthesia. They are named after John Olney, who conducted a study in 1989 to investigate neurotoxicity caused by PCP and related drugs. They are important for two reasons. Firstly, NMDA receptor antagonist drugs are not only street drugs that are taken recreationally, they are also physician-prescribed drugs for therapeutic treatment of human diseases such as memantine for Alzheimer's disease and amantadine for Parkinson's disease. Secondly in the field of anesthesiology, the dissociative anesthesia of many general anesthetics is due to NMDA receptor antagonist properties. Because the neuronal vacuolation of Olney's lesions evolves into neuronal necrosis or death of neurons, it is important to determine whether Olney's lesions occur in humans, not only in experimental animals. The essential question is whether an NMDA receptor antagonist drug is to be considered a human neurotoxin or not. The patient safety implications for pharmacotherapy and for anesthesia would each be profound, if the answer is affirmative.
In 1989, Olney et al. discovered that neuronal vacuolation and other cytotoxic changes ("lesions") occurred in brains of rats administered NMDA antagonists, including PCP, MK-801 (dizocilpine) and ketamine. Examination of neurons in the posterior cingulate and retrosplenial cortices by electron micrograph revealed apparent lytic breakdown of mitochondria in the large vacuoles which had become apparent 2 hours after administration of an NMDA antagonist. After administration of 1.0 (mg/kg sc) MK-801 to rats, these neurotoxic changes became more apparent until about 12 hours post-dose, but the morphology of most cells appeared normal by light microscope about 24 hours post-dose. With 10 (mg/kg sc) doses of MK-801, the vacuolation reaction was still visible by light microscope 48 hours post-dose. After repeated doses of the NMDA antagonists MK-801 and PCP, the vacuolation reaction appeared consistent with the reaction after a single dose, so there was no evidence of a cumulative neurotoxic effect or that the reaction proceeded to an irreversible stage with repeated doses. The lowest doses of ketamine and tiletamine that produced neurotoxic changes visible by light microscope 4 hours post dose were 40 (mg/kg sc) and 10 (mg/kg sc), respectively. The potency of the drugs in producing these neurotoxic changes corresponded with their potency as NMDA antagonists: i.e. MK-801 > PCP > tiletamine > ketamine.
Researcher Roland N. Auer conducted similar studies to look at the correlation between age and sex and the development of NMDA receptor antagonist neurotoxicity in test rats. Older rats experienced a much higher mortality rate after the development of NAN. Female rats were found, at all ages, to have a higher incidence of necrotic (dead) neurons as a result of NAN.